Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)
Epistemonikos ID: 0d80873784cf3e459ffbaabfdc261eb88fdf67c9
First added on: May 08, 2024